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Abstract
Objective—Presymptomatic individuals with the Huntingtin (HTT) CAG expansion mutation
that causes Huntington’s disease may have higher levels of depressive symptoms than healthy
comparison populations. However, the prevalence of HTT CAG repeat expansions among
individuals diagnosed with major depressive disorder has not been established.
Method—This was a case-control genetic association study of HTT CAG allele size in two
discovery cohorts of individuals with major depressive disorder and comparison subjects without
major depression as well as a replication cohort of individuals with major depression and
comparison subjects without major depression.
Results—CAG repeat lengths of 36 or greater were observed in six of 3,054 chromosomes from
individuals with major depression, compared with none of 4,155 chromosomes from comparison
subjects. In a third cohort, one expanded allele was observed among 1,202 chromosomes in the
major depression group, compared with none of 2,678 chromosomes in comparison subjects. No
clear pattern of clinical features was shared among individuals with the expanded repeats.
Conclusions—In clinical populations of individuals diagnosed with major depression,
approximately 3 in 1,000 carried expanded HTT CAG alleles.
Huntington’s disease is a progressive, dominantly inherited neurodegenerative disorder
characterized by motor and cognitive symptoms. It is caused by a mutation in one copy of
the Huntingtin (HTT) gene, comprising an expanded version of a polymorphic CAG
trinucleotide repeat (1,2). Normal chromosomes possess CAG alleles ranging from six to 34
units. Repeat expansions of 40 units or more are fully penetrant and lead to onset of overt
clinical symptoms, with age at onset inversely correlated with the repeat length, whereas
repeats of 36–39 units may exhibit reduced penetrance (3). Recent reports underscore the
prevalence of psychiatric symptoms in Huntington’s disease as well, particularly depression,
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irritability, and impaired impulse control, which may be present early in the disease course
(4) or even precede the characteristic chorea by 10 years or more (5). In one study of
presymptomatic Huntington’s disease repeat carriers, for example, study subjects displayed
greater levels of irritability as well as cognitive symptoms (6).
Studies of the pathophysiology of major depressive disorder have revealed associated
changes in striatal perfusion at rest (7) and during reward processing (8–10) and learning
tasks (11). Recently, direct stimulation of striatum has shown evidence of efficacy in
difficult-to-treat major depression (12). More broadly, high rates of depression are observed
across basal ganglia diseases (13,14), including caudate stroke (15). Likewise, a growing
body of evidence suggests glutamatergic abnormalities in major depression (16), and
glutamatergic drugs may exhibit antidepressant effects (17). Thus, both in clinical
presentation and in pathophysiology, similarities between Huntington’s disease and major
depressive disorder are apparent.
Recent studies suggest that a small but definable proportion of apparent cases of psychiatric
disorders such as schizophrenia may be accounted for by rare copy-number variations. One
example is the 22q11 deletion associated with velocardiofacial syndrome, present in
multiple studies of clinical samples of schizophrenia patients (18,19). While it is known that
even “presymptomatic” carriers of the Huntington’s disease risk allele may exhibit mood
symptoms, it has been assumed that carriers would still be extremely rare in clinical
populations with major depression. To our knowledge, only one small study has examined
the HTT CAG repeat in patients diagnosed with major depression, and it found no expanded
alleles among 16 patients (20). Thus, from a clinical perspective, it is unknown how
commonly individuals presenting with major depression carry risk alleles for Huntington’s
disease.
To better characterize the prevalence of HTT CAG repeats in clinical populations with major
depression, we first examined HTT CAG repeat length in two cohorts of affected
individuals, including one drawn from the Sequential Treatment Alternatives to Relieve
Depression (STAR*D) cohort, and in comparison subjects. We hypothesized that expanded
HTT alleles would be over-represented among individuals with major depression relative to
comparison subjects. To attempt to replicate initial findings, we then examined repeat length
in a third cohort of patients with major depression and comparison subjects.
Method
Clinical Cohort 1
As part of a study of genetic influences on neuroimaging phenotypes, the Phenotype
Genotype Project (21), three groups of individuals were recruited through newspaper
advertisements or referrals from psychiatric clinics: individuals with major depressive
disorder, individuals with cocaine use disorders, and a healthy comparison group matched
for age, sex, education, and ethnicity. All participants underwent a clinical interview that
included the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID; 22). Race
was determined by self-identification on a standardized form (23). Participants also
completed the Inventory of Depressive Symptomatology–Self Report (24,25) and the
Edinburgh Handedness Inventory (26). Participants had to be 18–55 years of age and have
no current or lifetime DSM-IV axis I disorder or major medical illness known to influence
brain structure or function, including neurologic disease, HIV, and hepatitis C. All
participants provided written informed consent, and the protocol was approved by the
institutional review board of Massachusetts General Hospital. In the major depression group
(N=34), the mean age was 38.4 years (SD=11.2), all were Caucasian, and 47.1% were
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women. In the comparison group (N=74), the mean age was 34.8 years (SD=11.9), all were
Caucasian, and 46.0% were women.
Clinical Cohort 2
The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study was a
multicenter study conducted in the United States with more than 4,000 individuals who
presented to primary or specialty care clinics for treatment of depression. Details of the
STAR*D protocol and clinical results have been presented previously (27,28). DNA was
collected for 1,932 of the participants and was made available to us in an anonymized form
by the National Institute of Mental Health; DNA from 1,493 self-reported Caucasian
participants was used in the present analysis. In this group, 61.0% were women, and the
mean age was 42.7 years (SD=13.5). The STAR*D clinical and genetics protocols were
approved by the institutional review boards of participating institutions. Because the DNA
was provided in anonymized form, the Massachusetts General Hospital institutional review
board determined that the study protocol did not represent human subjects research.
Determining an appropriate comparison group for this study was complicated by the late
onset of Huntington’s disease and by the fact that, to our knowledge, the HTT CAG repeat
has not been examined in large non-Huntington’s cohorts. Therefore, because Huntington’s
disease is a relatively uncommon dominantly inherited disorder (1 in 10,000), we used as an
initial comparator for this cohort CAG repeat frequency on the second chromosome (i.e., the
one with the shorter repeat) in large cohorts of patients with Huntington’s disease
(N=4,007), which should reflect the underlying population distribution of the HTT CAG
allele.
Clinical Cohort 3
Patients with a clinical diagnosis of major depression were recruited from consecutive
admissions to the inpatient unit of the Department of Psychiatry and Psychotherapy of the
University of Bonn, Germany. DSM-IV diagnosis was made by psychiatrists or
psychologists applying a consensus best-estimate procedure based on all available
information, including a structured interview (the SCID), medical records, and family
informants when available. All patients (N=601) included in the study were of Caucasian
ancestry, based on self-reported information about grandparents. The mean age at interview
was 47.4 years (SD=13.8), and the mean age at onset of major depression, defined as when
DSM-IV criteria were fulfilled for the first time, was 36.4 years (SD=13.2). The cohort was
63.7% women.
The comparison sample (N=1,339) was recruited within the framework of the German
National Research Project in the region of Bonn to serve as a comparison sample for genetic
studies of several neuropsychiatric phenotypes. Population-based recruitment was performed
in collaboration with the local census bureau. Participants were evaluated by an experienced
psychiatrist and screened for neurological and psychiatric disorders with a structured
questionnaire. The mean age at interview was 47.8 years (SD=15.3), and the cohort was
52.2% women.
All participants provided written informed consent. All participants also consented to
transfer of DNA and phenotypic data in an anonymized fashion to other research groups.
Protocols and procedures were approved by the local ethics committees.
Molecular Methods
HTT CAG repeat allele sizes were determined by polymerase chain reaction (PCR) using an
assay that does not include the adjacent proline (CCG) repeat and that is a modification of
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the method reported by Warner and colleagues (29). HTT CAG repeat sizes were determined
by using a fluorescently labeled/ tailed primer pair, CAG1-6FAM-
ATGAAGGCCTTCGAGTCCCT-CAAGTCCTTC and CAG2-
GGCGGTGGCGGCTGTTGCTGCT-GCTGCTGC. The PCR conditions were as follows:
80 ng of genomic DNA, 1.25 mmol MgCl2, 1X Buffer II (Applied Biosystems), 0.5 U
AmpliTaq Gold (Applied Biosystems), 0.125 μmol each primer, 0.25 mmol
deoxyribonucleotide triphosphate, and 12% dimethyl sulfoxide in a 10 μL reaction. The
cycling conditions for the reaction were as follows: initial denaturation at 94°C for 4
minutes, followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 65°C
for 30 seconds, extension at 72°C for 45 seconds, and a final extension of 10 minutes at
72°C. The PCR products were run on an Applied Biosystems 3730XL DNA Analyzer with
GeneScan500 LIZ (Applied Biosystems) as the internal size standard. The data were
analyzed with GeneMapper v3.7 (Applied Biosystems), and the sizes were converted to
CAG repeat number based on comparison to known CAG repeat number standards.
Analysis
We defined HTT risk alleles (completely or incompletely penetrant) a priori as those with a
length ≥36, the threshold at which Huntington’s disease risk appears to emerge (3). Fisher’s
exact test was used to compare frequency of HTT risk alleles among case and comparison
subjects.
Power for an alpha level of 0.05 was estimated by simulation using the PLINK software tool
set (30), assuming a genotype relative risk of 6 and a minor allele frequency of 0.001, using
Fisher’s exact test. Power to detect association under these conditions was 23.5%. Stata 10.0
(Stata Corp., College Station, Tex.) was used for all analyses.
Results
In cohort 1, two of 68 chromosomes from patients with major depression had HTT CAG
repeat allele sizes ≥36 (lengths of 36 and 37), compared with none of 148 chromosomes
from participants in the comparison group (Fisher’s exact test, p=0.098). In cohort 2, a total
of four alleles of 36 repeats or greater were observed (lengths of 36, 37, 38, and 42) among
2,986 chromosomes from depressed subjects, compared with none of 4,007 control
chromosomes (Fisher’s exact test p=0.006). Figure 1 shows the distribution of HTT allele
lengths among patients with major depression and healthy comparison subjects in this
second cohort.
In the replication cohort (cohort 3), one expanded allele (N=38) was identified among 1,202
chromosomes from patients with major depression, and none of 2,678 chromosomes from
comparison subjects (Fisher’s exact test, p=0.31). For the three cohorts combined, we
observed 7/4,256 expanded alleles compared with 0/6,833 among comparison chromosomes
(Fisher’s exact test, p=0.001).
Table 1 compares demographic and clinical features for four participants with allele lengths
≥36 with the remainder of cohort 2. No pattern of sociodemographic or clinical features was
apparent. Of note, the one participant with an allele length of 42 (i.e., in the fully penetrant
Huntington’s disease range) showed clinical improvement with citalopram treatment.
Structural neuroimaging in 84 participants from cohort 1 (34 with major depression, 50
comparison subjects) indicated that caudate volumes for two individuals with major
depression with expanded alleles and for the major depression cohort as a whole were not
significantly smaller in volume relative to those of comparison subjects. (The normalized
caudate volumes were 0.60 [SD=0.01] for each group; see the data supplement that
accompanies the online edition of this article.)
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We identified seven expanded CAG repeats among patients with major depression and none
among healthy comparison subjects after examining a total of 11,089 chromosomes. While
the distribution of HTT CAG allele lengths in unselected populations has not been well
established, our results suggest that low-end Huntington’s disease-associated alleles are
overrepresented among individuals diagnosed with major depression. Specifically, our
results would estimate that ∼7/2,128, or 3.3 in 1,000, individuals diagnosed with major
depression carry an expanded HTT CAG allele (95% confidence interval=0.9–5.7).
The most straightforward interpretation of our results would suggest that all of these
individuals will ultimately develop Huntington’s disease with time and that the depressive
symptoms simply represent a prodromal presentation, as other studies have suggested (5,6).
Indeed, all of the patients with major depression reported on here are below the predicted
age at onset of Huntington’s disease based on repeat number (31,32). This interpretation
would suggest a parallel with the 22q11 deletion associated with velocardiofacial syndrome
but also seen in clinical samples of patients previously diagnosed with apparent
schizophrenia (18,19). While one could hypothesize some enrichment of expanded
Huntington’s disease alleles among individuals with depressive or irritable symptoms, our
results indicate a greater-than-expected prevalence among individuals diagnosed with major
depression. They would underscore the importance of inquiring about family history of
movement disorder and, where indicated, performing a careful neurologic examination in
individuals with depressive symptoms.
Alternatively, our results may shed light on the phenotype corresponding to incompletely
penetrant alleles. Molecular studies indicate that the CAG repeat length affects
mitochondrial ADP phosphorylation (33), even for CAG repeat lengths in the intermediate
range. However, no clinical phenotype has previously been described for these low-end HTT
alleles, except when they cause the overt clinical symptoms of Huntington’s disease. Our
results would also be consistent with a model in which incompletely penetrant alleles are
associated with risk for presenting with depressive symptoms even if they never lead to the
movement disorder characteristic of Huntington’s disease. This hypothesis may merit
investigation in presymptomatic Huntington’s disease cohorts. The mean age of individuals
with expanded CAG repeats here is more than two decades before the predicted onset age of
motor symptoms based on allele length, and thus earlier than psychiatric symptoms are
typically reported (31,32). Notably, data from a Huntington’s disease mouse model suggest
that the antidepressant fluoxetine improves depression-like behaviors associated with
characteristic Huntington’s disease pathology (34), which might explain the observed
benefit of antidepressant treatment in some of the cases identified in our study.
Limitations of this study include the absence of a neurologic examination of sufficient scope
to rule out Huntington’s disease motor symptoms in cohort 2 and the absence of systematic
collection of family history of neurologic diseases in any of the three cohorts. Therefore, we
cannot exclude the possibility of unrecognized Huntington’s disease, particularly in cohort
2, although it is important to underscore that for all participants in the depression group, the
primary diagnosis was major depressive disorder, and thus individuals with known or
suspected Huntington’s disease would not have been enrolled. As DNA was provided to us
in an anonymized fashion and recontact with participants was prohibited by the institutional
review board, it is impossible to obtain further neurologic examination or longitudinal
follow-up data to determine which of these individuals will develop Huntington’s disease
motor symptoms. With this limitation in mind, more detailed clinical characterization and
longitudinal observations of individuals with HTT CAG alleles in the incompletely penetrant
range would be of great value.
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We also caution that the power to detect association is limited (~23.5%) even with multiple
large cohorts, because the risk variant is rare. For a genome-wide study, the risk of spurious
association (i.e., a low posterior probability) would be great under these conditions, as both
prior probability for any given locus and power are low. Conversely, in the present study,
where only one locus was tested based on a high prior probability of association, the
posterior probability would be substantially greater despite modest power. Still, analysis of
additional cohorts of patients with major depression and comparison subjects will be
important to estimate the risk allele frequency with greater precision.
These results add to a growing body of literature suggesting that major depression is a
heterogeneous illness whose presentation overlaps with neurodegenerative disorders. That
is, some individuals presenting with a major depressive episode may be prodromal for a
neurodegenerative illness. For three of the paradigmatic neurodegenerative disorders—
Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease—depressive symptoms
may precede other typical disease symptoms, in some cases by a decade or more (5,6,35,36).
In Parkinson’s disease, there is evidence of shared disease liability with depression: first-
degree relatives of individuals with Parkinson’s disease are at elevated risk for depressive
and anxiety disorders (37). Carriers of risk genes for other neurologic disorders believed to
affect the basal ganglia, such as DYT1 in idiopathic torsion dystonia, likewise have an
elevated risk for recurrent major depression (38). Further studies examining disease risk
genes for neurodegenerative disorders, particularly those affecting the basal ganglia, among
cohorts with major depression may help to elucidate the pathophysiology underlying
depressive symptoms in general. These studies may also help to clarify the utility of further
examination for neurologic disorders in patients presenting with a major depressive episode.
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TABLE 1
Clinical and Demographic Characteristics of Participants With Major Depressive Disorder With ≥36 Repeat
Alleles (“Expanded”) and Remainder of Cohort
Characteristic Expanded (N=4) Remainder of Cohort (N=1,489)
N % N %
Male 3 75 547 38
Recurrent illness 3 75 1,065a 77
Lifetime suicide attempt 1 25 208 14
Family history of major depression 3 75 841 57
Remission with citalopram 2 50 610 41
Mean Range Mean SD
Age (years) 38.0 33–43 42.7 13.4
Age at illness onset (years) 21.3 8–39 26.1 14.9
Quick Inventory of Depressive Symptomatology–Clinician-Rated
 Baseline score 17.0 12–22 16.3 3.4
 Baseline psychomotor agitation item score 1.2 0–2 1.0 0.8
 Endpoint score 8.7 4–15 8.5 5.8
a
Data available for 1,385 participants.
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